HANA PHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,300 KRW | 0.00% |
|
+0.76% | -4.66% |
| Sales 2019 * | 168B 121M 10.1B | Sales 2020 * | - | Capitalization | 236B 171M 14.24B |
|---|---|---|---|---|---|
| Net income 2019 * | 28B 20.22M 1.69B | Net income 2020 * | - | EV / Sales 2019 * | 0.49 x |
| Net cash position 2019 * | 154B 111M 9.28B | Net cash position 2020 * | - 0 0 | EV / Sales 2020 * | - |
| P/E ratio 2019 * |
8.28
x | P/E ratio 2020 * |
-
| Employees | - |
| Yield 2019 * |
2.97% | Yield 2020 * |
-
| Free-Float | 36.99% |
More Fundamentals
* Assessed data
More news
| 1 week | +0.76% | ||
| Current month | -3.27% | ||
| 1 month | -3.27% | ||
| 3 months | -2.35% | ||
| 6 months | -1.26% | ||
| Current year | -4.66% |
1 week
13 170.00
13 490.00
1 month
13 090.0013 860.00
Current year
13 090.0014 940.00
1 year
13 090.0016 190.00
3 years
13 090.0023 900.00
5 years
13 090.0026 454.52
10 years
13 090.0034 954.51
| Managers | Title | Age | Since |
|---|---|---|---|
Tae-Hong Choi
CEO | Chief Executive Officer | 67 | - |
Hong-Ju Yoon
DFI | Director of Finance/CFO | 47 | 01/02/01 |
Yong-Yeon Hwang
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tae-Hong Choi
CEO | Chief Executive Officer | 67 | - |
Sang-Soo Cho
BRD | Director/Board Member | 61 | - |
Dong-Hun Jo
BRD | Director/Board Member | 43 | 01/06/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 13,300 | 0.00% | 16 824 |
| 29/24/29 | 13,300 | -0.08% | 25,037 |
| 26/24/26 | 13,310 | +0.08% | 10,523 |
| 25/24/25 | 13,300 | -0.89% | 5,981 |
| 24/24/24 | 13,420 | +0.83% | 10,802 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.66% | 172M | |
| +3.37% | 69.85B | |
| +11.77% | 8.98B | |
| -12.75% | 4.89B | |
| +42.38% | 4.44B | |
| +5.23% | 3.95B | |
| +21.69% | 2.49B | |
| -19.05% | 2.4B | |
| -28.72% | 2.28B | |
| +11.13% | 1.96B |
- Stock Market
- Equities
- A293480 Stock
